0000899243-23-006730.txt : 20230302 0000899243-23-006730.hdr.sgml : 20230302 20230302160534 ACCESSION NUMBER: 0000899243-23-006730 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230228 FILED AS OF DATE: 20230302 DATE AS OF CHANGE: 20230302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zeng Ling CENTRAL INDEX KEY: 0001824252 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40657 FILM NUMBER: 23698837 MAIL ADDRESS: STREET 1: C/O DICERNA PHARMACEUTICALS, INC. STREET 2: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Omega Therapeutics, Inc. CENTRAL INDEX KEY: 0001850838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 20 ACORN PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: (617) 949-4360 MAIL ADDRESS: STREET 1: 20 ACORN PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-28 0 0001850838 Omega Therapeutics, Inc. OMGA 0001824252 Zeng Ling C/O OMEGA THERAPEUTICS, INC. 20 ACORN PARK DRIVE CAMBRIDGE MA 02140 0 1 0 0 See Remarks Option (Right to Buy) 6.46 2023-02-28 4 A 0 55000 0.00 A 2033-02-27 Common Stock 55000 55000 D The options vest and become exercisable with respect to 25% of the underlying shares on February 28, 2024 and in equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 28, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Chief Legal and Administrative Officer /s/ Barbara Chan as Attorney-in-Fact for Ling Zeng 2023-03-02